Predictive Oncology Inc.

Equities

POAI

US74039M3097

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-10 pm EDT			5-day change	1st Jan Change
1.63 ^USD	-7.39%		-9.94%	-50.46%

May. 01	Wall Street Set to Open Lower Ahead of Fed Rate Decision; Private Employment Figures Top Forecasts	MT
May. 01	Investors Await Fed Rate Decision as US Futures Trend Lower in Wednesday's Premarket	MT

Predictive Oncology Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022

August 11, 2022 at 05:11 pm EDT

Predictive Oncology Inc. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported sales was USD 0.371591 million compared to USD 0.350207 million a year ago. Net loss was USD 10.39 million compared to USD 2.57 million a year ago. Basic loss per share from continuing operations was USD 3 compared to USD 1 a year ago. Diluted loss per share from continuing operations was USD 3 compared to USD 1 a year ago.
For the six months, sales was USD 0.686159 million compared to USD 0.630524 million a year ago. Net loss was USD 13.76 million compared to USD 6.46 million a year ago. Basic loss per share from continuing operations was USD 4 compared to USD 3 a year ago. Diluted loss per share from continuing operations was USD 4 compared to USD 3 a year ago.

Latest news about Predictive Oncology Inc.

Wall Street Set to Open Lower Ahead of Fed Rate Decision; Private Employment Figures Top Forecasts	May. 01	MT
Investors Await Fed Rate Decision as US Futures Trend Lower in Wednesday's Premarket	May. 01	MT
Top Premarket Gainers	May. 01	MT
Predictive Oncology Inc. Announces Significant Progress with FluGen in Development of Intranasal Flu Vaccine	Apr. 30	CI
FUJIFILM Wako Chemicals U.S.A. Corporation and Predictive Oncology Announce Collaboration to Reduce Protein Interference in Bacterial Endotoxin Detection Testing of Biopharmaceuticals	Apr. 25	CI
Transcript : Predictive Oncology Inc., Q4 2023 Earnings Call, Apr 01, 2024	Apr. 01
Predictive Oncology Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
Predictive Oncology Inc. Announces Resignation of Pamela Bush, as Chief Business Officer, Effective from February 15, 2024	Feb. 08	CI
Transcript : Predictive Oncology Inc., Q3 2023 Earnings Call, Nov 14, 2023	Nov. 14
Earnings Flash (POAI) PREDICTIVE ONCOLOGY Posts Q3 Revenue $715,056	Nov. 14	MT
Predictive Oncology Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Predictive Oncology Inc. Announces Chief Financial Officer Changes	23-08-17	CI
Predictive Oncology Inc. Announces Executive Changes	23-08-17	CI
Transcript : Predictive Oncology Inc., Q2 2023 Earnings Call, Aug 10, 2023	23-08-10
Earnings Flash (POAI) PREDICTIVE ONCOLOGY Posts Q2 Revenue $490,110	23-08-10	MT
Predictive Oncology Inc. Reports Impairment Charges for the Second Quarter Ended June 30, 2023	23-08-10	CI
Predictive Oncology Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Predictive Oncology Relocates Corporate Headquarters to Pittsburgh Facility	23-07-18	MT
Predictive Oncology Inc. Appoints Andrew Einhorn to Its Business Advisory Board	23-06-27	CI
Predictive Oncology Inc. Appoints Dr. Bernard A. Harris, Jr. to Its Newly Formed Business Advisory Board	23-06-20	CI
Transcript : Predictive Oncology Inc., Q1 2023 Earnings Call, May 15, 2023	23-05-15
Earnings Flash (POAI) PREDICTIVE ONCOLOGY Posts Q1 Revenue $239,895	23-05-15	MT
Predictive Oncology Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Predictive Oncology Inc. Appoints Veena Rao to Its Board of Directors	23-05-02	CI
Wall Street Set to Open Flat Amid Mixed Earnings Reports, Ahead of April PMI Data	23-04-21	MT

Chart Predictive Oncology Inc.

Duration

Period

More charts

Company Profile

Predictive Oncology Inc. is a knowledge-driven company focused on applying artificial intelligence (AI) to support the development of cancer therapies. The Company operates through three segments: Pittsburgh, Birmingham, and Eagan. Pittsburgh segment provides services, which include the application of artificial intelligence (AI) using its proprietary biobank of 150,000 plus tumor samples. Pittsburgh segment also develops tumor-specific in vitro models for oncology drug discovery and research. Birmingham segment focuses on contract services and research for biopharmaceutical company clients and academic collaborators, focused on solubility improvements, stability studies, and protein production. Specifically, Birmingham provides optimized formulations for vaccines, antibodies, and other protein therapeutics. Eagan segment produces the STREAMWAY System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-05-14 - Q1 2024 Earnings Release

More about the company

	1st Jan change	Capi.
PREDICTIVE ONCOLOGY INC.	-50.46%	6.69M
ABBOTT LABORATORIES	-4.84%	182B
MEDTRONIC PLC	+0.56%	110B
BECTON, DICKINSON AND COMPANY	-3.35%	68.11B
DEXCOM, INC.	+2.39%	50.53B
CENCORA, INC.	+9.36%	44.8B
HOYA CORPORATION	+2.84%	40.7B
METTLER-TOLEDO INTERNATIONAL, INC.	+24.51%	32.25B
WEST PHARMACEUTICAL SERVICES, INC.	+3.43%	26.53B
TERUMO CORPORATION	+15.25%	25.02B

Other Medical Equipment, Supplies & Distribution